Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp453 | Osteoporosis: treatment | ECTS2013

Factors influencing levels of bone resorption during denosumab dosing

Eastell Richard , Siris Ethel , Roux Christian , Black Dennis M. , Franchimont Nathalie , Jang Graham , Daizadeh Nadia , Wagman Rachel B. , Austin Matt

Denosumab treatment is associated with low fracture incidence, sustained BMD increases, and reduced sCTX. The decrease in median sCTX is at the quantifiable limit (0.049 ng/ml) one month post-dose, remains low, and attenuates at the end of the 6-month dosing interval. Using 7 years of data from the FREEDOM study and its extension, we characterized changes in sCTX over time and the influencing factors. In the bone turnover marker and pharmacokinetic substudies, serum was collec...

ba0001oc1.1 | Osteoporosis epidemiology and long term treatment complications | ECTS2013

Disease-specific perception of fracture risk and incident fracture rates among postmenopausal women: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW)

Gregson Celia , Dennison Elaine , Compston Juliet , Adami Silvano , Adachi Jonathan , Anderson Frederick , Boonen Steven , Chapurlat Roland , Diez-Perez Adolfo , Greenspan Susan , Hooven Frederick , Lacroix Andrea , Nieves Jeri , Netelenbos J Coen , Pfeilschifter Johannes , Rossini Maurizio , Roux Christian , Saag Kenneth , Silverman Stuart , Siris Ethel , Watts Nelson , Wyman Allison , Cooper Cyrus

Patients with improved health understanding have greater autonomy over, and motivation towards, health-related lifestyles. We compared self-perceived fracture risk and 3-year incident fracture rates in postmenopausal women for a range of co-morbid diseases using data from the Global Longitudinal study of Osteoporosis in Women (GLOW).GLOW is an international cohort study involving 723 physician practices across 10 countries in Europe, North America, Austr...